Covidien drops renal denervation program

Candace Stuart | | Cardiovascular Business | Vascular & Endovascular

Covidien pulled the plug on its renal denervation initiative, citing “slower than expected development of the renal denervation market.”

Covidien’s decision to shutter its OneShot renal denervation effort comes on the heels of an announcement by Medtronic that the SYMPLICITY HTN-3 clinical trial failed to meet its efficacy endpoint. The therapy is being developed as a treatment for uncontrolled hypertension.

Dublin-based Covidien reported that it would not proceed with its RAPID II trial (Rapid Sympathetic Denervation for Resistant Hypertension II). The randomized clinical trial was designed to compare patients who received bilateral renal ablation with the OneShot system to patients who received no intervention. The system, which uses an over-the-wire balloon-based irrigated catheter technology, received CE mark in Europe in 2012 but was not yet approved for use in the U.S.

Covidien will continue to work with physicians and enrolled patients in RAPID II on a transition strategy. It said in a release that the company “believes that the long-term hypertension market remains attractive and will continue to explore opportunities in this area.”

Candace Stuart, Contributor

Related Content

IVUS-guided PCI reduces risks in patients with diabetes
LAAC with Watchman FLX reduces bleeding risks after AFib ablation
Bioresorbable BTK stent superior to ballon angioplasty at 2 years
Shockwave Medical’s IVL technology delivers more positive outcomes for PAD patients
Standing desks fail to lower blood pressure or minimize heart risks—they may even do damage
IVL vs. RA for chronic total occlusion PCI: Key data cardiologists should know

Around the web

Health Imaging
Use of AI opportunistic screening in CT for cardiovascular disease

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.

Health Imaging
New imaging protocols proposed to curb rise of cardiovascular infections

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.

Radiology Business
What does radiology have to do with climate change?

Kate Hanneman, MD, explains why many vendors and hospitals want to lower radiology's impact on the environment. "Taking steps to reduce the carbon footprint in healthcare isn’t just an opportunity," she said. "It’s also a responsibility."